Trump proposes tariff on generic drugs, threatening Indian pharma exports

President Donald Trump has proposed a tariff on generic drugs imported into the United States, a move that directly threatens India's pharmaceutical industry, which supplies nearly 40% of the generic medicines consumed in the U.S. market. The tariff, part of a broader trade policy aimed at reducing reliance on foreign manufacturing, would increase costs for Indian drugmakers such as Sun Pharma, Dr. Reddy's, and Cipla, which derive a significant portion of their revenue from U.S. sales. The proposal comes amid ongoing trade tensions and could lead to higher drug prices for American consumers, potentially straining healthcare budgets. Indian pharmaceutical stocks fell sharply on the news, with the Nifty Pharma index dropping over 3% in a single session. Industry bodies in India have urged the government to negotiate with the U.S. to avoid the tariff, warning of job losses and reduced investment in research and development. The tariff would also disrupt global supply chains for essential medicines, as many active pharmaceutical ingredients (APIs) are sourced from India and China.

Global Impact

Economically, the tariff would raise U.S. healthcare costs by billions annually, as generic drugs account for 90% of prescriptions but only 20% of spending. Politically, it strains U.S.-India trade relations, potentially prompting retaliatory tariffs on American agricultural or tech exports.